On December 12, 2023, local time, Chilean President Gavriel Borich met with Yin Weidong, Chairman, President and CEO of SINOVAC, and his delegation at the Presidential Palace. The two sides reached an agreement on the localization of vaccine production and cooperation in the research and development of health products, and the Chilean government will strongly support SINOVAC's project promotion in the region.

President Borich began by recalling his successful visit to China not long ago, emphasizing that when he met with President Xi Jinping, they jointly identified the need to further deepen cooperation in the health sector among the many bilateral cooperation between China and Chile. He also indicated that the Chilean government has set the strategic goal of developing vaccine R&D and industrialization in Chile.

Chairman Yin Weidong responded, "His Excellency the President's visit to China was indeed a great success, and the charisma you displayed attracted many Chinese people and received unanimous praise. This time, our delegation from SINOVAC visited Chile specifically to better implement the consensus reached by the top leaders of the two countries, and to study how to accelerate the cooperation between China and Chile in vaccine research and development and industrialization construction and other projects." Developing vaccine R&D and industrialization projects in Chile as the company's long-term strategy, SINOVAC will unswervingly promote this goal, which is highly consistent with the strategic direction of the Chilean government.

Yin Weidong said that the two sides have set up a special working group to make full use of Chile's successful anti-epidemic experience during the SINOVAC epidemic, maximize Chile's R&D strengths in the field of biomedicine as well as SINOVAC SINOVAC's strengths in R&D and industrialization in the field of vaccines, so as to respond to pandemics of infectious diseases in a more efficient way, increase the availability and affordability of vaccines, and make contributions to the safeguarding of health and well-being for the populations of Chile and many more countries in South America. We will contribute to the health and well-being of more people in Chile and South America.

In fact, in order to help Chile and neighboring countries fight against infectious disease epidemics, SINOVAC and local partners have carried out cooperation in various aspects from vaccine supply to clinical research. During the meeting, Mr. Weidong Yin specifically mentioned the real-world study of the SINOVAC vaccine conducted in Chile, which was finally published in the New England Journal of Medicine. Chile was one of the first countries to approve the emergency use of SINOVAC's inactivated COVID-19 vaccine, Kerlaflex®, after the outbreak, and Kerlaflex® is the most widely used COVID-19 vaccine in Chile after the country launches its national mass vaccination at the beginning of February 2021," said Mr. Yin.

In addition to the New Crown vaccine, SINOVAC's influenza vaccine and inactivated hepatitis A vaccine have also been approved for registration in Chile. In addition, SINOVAC and the Millennium Institute of Immunology and Immunotherapy of the Pontifical Catholic University of Chile are jointly conducting clinical studies on several vaccines, including the quadrivalent influenza virus lysate vaccine.

During the presidential meeting on the same day, Nicolás Grau, Chilean Minister of Economy, Aisén Etcheverry, Chilean Minister of Science, Andrea Albagli, Chilean Deputy Minister of Health, and Weining Meng, Chairman of the SINOVAC Quality Committee and Head of Latin America, Barbara, Regulatory Director of SINOVAC Chile, etc. participated in the discussion.

https://mp.weixin.qq.com/s/YmSQ1oQcRnrKRSXcj4cgiA